Medplus Subsidiary Receives Drug License Suspensions Across Three Karnataka Stores

Medplus Subsidiary Receives Drug License Suspensions Across Three Karnataka Stores
<h1>Medplus Subsidiary Receives Drug License Suspensions Across Three Karnataka Stores</h1>

<p>Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services Limited, has received multiple suspension orders concerning drug licenses for stores operating in the state of Karnataka. The actions were initiated by various authorities regarding contraventions under Rule 65 of the Drugs and Cosmetics Act, 1940 and associated Rules.</p>

<p>The regulatory actions resulted in suspensions across three different store locations within the state. These operational challenges carry a quantifiable potential revenue loss for the entity. The details of the licenses, the governing authorities, and the impact are summarized below:</p>

<table>
<thead>
<tr>
<th>Authority</th>
<th>Store Location Details</th>
<th>Duration of Suspension</th>
<th>Order Received Date</th>
<th>Potential Revenue Loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assistant Director, Drugs Control (Administration Bangalore Circle-3)</td>
<td>Sarakki JP Nagar Metro Station store in Karnataka</td>
<td>One day</td>
<td>14.07.2026</td>
<td>Rs 0.77 lacs</td>
</tr>
<tr>
<td>Assistant Director, Drugs Control (Administration Bangalore Circle-3)</td>
<td>Jaraganahalli store in Karnataka</td>
<td>One day</td>
<td>14.07.2026</td>
<td>Rs 0.35 lacs</td>
</tr>
<tr>
<td>Assistant Director, Drugs Control (Belgaum Circle)</td>
<td>K C Road Chikkodi store in Karnataka</td>
<td>Two days</td>
<td>14.07.2026</td>
<td>Rs 0.47 lacs</td>
</tr>
</tbody>
</table>

<p>The suspension orders relate to alleged violations of Rule 65 of the Drugs and Cosmetics Act, 1940 and the corresponding Rules for all three incidents. The affected stores are situated in Bangalore Circle-3 (Bangalore) and Belgaum Circle.</p>

MEDPLUS Stock Price Movement​

Shares of Medplus Health Services Limited today shed 0.91% in trading to settle at ₹806.95. The stock saw a volume of 130,211 shares during the session.
 

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.

Back
Top